Prelude Therapeutics Incorporated (PRLD)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Prelude Therapeutics Incorporated (PRLD) Q3 2025 Earnings Call Transcript
Prelude Therapeutics Incorporated ( PRLD ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Bryant Lim - CFO, Chief Legal Officer & Corporate Secretary Krishna Vaddi - Founder, CEO & Director Peggy Scherle - Chief Scientific Officer Sean Brusky - Chief Business Officer Conference Call Participants Reni Benjamin - Citizens JMP Securities, LLC, Research Division Jiale Song - Jefferies LLC, Research Division Robert Burns - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, everyone, and welcome, everyone, to the Prelude Therapeutics Investor Conference Call.
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know
Prelude Therapeutics (PRLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)
Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
